4c15507. Additional experimental details; temperature and time-dependent dissolution of the PAAm with the DHEBA cross-linker; measurement of mechanical properties of the PAAm with the cleavable ...

Preliminary data from the first-in-human study presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated that CS5001 is well-tolerated and exhibits encouraging ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a ...

REHOVOT, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage ...

MS Annika is a crosslink search engine based on MS Amanda, aimed at identifying crosslinks of cleavable and non-cleavable crosslinkers from MS2 and MS3 spectra.

Corbus Pharmaceuticals (CRBP) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation, FTD, to CRB-701 ...

The three-year OS rate was 74% in the belantamab mafodotin combination arm and 60% in the daratumumab combination arm. The ...

CRB-701 has gained FDA fast track status for the treatment of adult patients with relapsed/refractory metastatic cervical ...

Cleavable linkers dominate the ADC market, driven by their versatility and therapeutic efficacy. Regulatory approvals and ongoing clinical trials underscore the growing adoption of cleavable linker ...

Iron oxide nanoparticles containing a nitric oxide-responsive cleavable linker allow in vivo magnetic resonance imaging and the quantification of nitric oxide with high sensitivity and selectivity ...

▎药明康德内容团队编辑  肿瘤免疫微环境复杂多变，其中的免疫激活细胞和免疫抑制细胞双方持续交战，免疫激活细胞CD8+ T因此逐渐耗竭。调节性T细胞（Treg）、MDSC（髓系来源的抑制细胞）等免疫抑制细胞数量众多、手段多样，是压制CD8+ T细胞杀伤肿瘤的重要力量，往往会阻碍免疫治疗的效果。因此，常规的肿瘤蛋白药物或 ...